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ABSTRACT
Objective: To demonstrate that micro-franchising system is an effective way of improving 
access to effective health care such as the introduction of first line antimalarias in 
populations living in underserved rural areas in Kenya.
Design:  A descriptive study. 
Setting: Child and family wellness (CFW) micro-franchised nurse run clinics in 
Kenya.
Results: In 2007, 39.3% of RDTs carried out were positive for malaria. All malaria 
positive (RDTs and microscopy) patients received artemether lumefantrine (AL) 
according to their weight in accordance with the Government approved treatment 
guidelines. During the same period a total of 3,248 community members were reached 
with malaria information, however, community expectations took longer to change as 
patients demanded AL even when the malaria diagnosis was negative. Initially, this 
led to the dispensing of other antimalarials to patients with malaria like symptoms 
even with a negative test. This demand decreased with more community education on 
the importance of the tests. Engaging the private sector though with challenges proved 
feasible and appropriate in accessing malaria treatment based on clinical diagnosis 
supported by RDTs to confirm the diagnosis instead of presumptive treatment based on 
fever. This led to a reduction of antimalarial prescriptions by more than 50%, implying 
better patient care, rational drug use as well as cost savings on malaria treatment.
Conclusion: A micro-franchising system is an effective and sustainable way of improving 
access to effective health care by populations living in underserved rural areas of 
Africa. With appropriate supportive training and supervision, the system can adapt 
to changes in treatment guidelines and to new regimens.
INTRODUCTION
Sustainable Healthcare Foundation (SHF) is a not-
for-profit organisation whose mission is to prevent 
needless death and illnesses through sustainable 
methods of improving access to essential drugs 
and basic health services for children and families 
in the resource scarce communities. SHF applies 
a solid business solution (franchising) to a vast 
public sector problem; it has adapted and refined 
the franchising model to deliver critical healthcare 
services to underserved populations. SHF recruits 
franchisees with previous health experience and takes 
them through standardised rigorous training, and 
applies strict quality control systems for consistency 
across the outlets. Those outlets that consistently 
under perform are revoked and replaced with new 
outlets (1). The programme started in 1999 with 
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11 drug shops and is currently running 65 outlets 
in ten districts of Kenya. The programme is being 
expanded to reach 225 outlets by 2012. The expanded 
programme will adopt new and more effective high 
quality interventions such as, access to basic health 
care, access to essential medicines, school health 
promotion safe water promotion, growth monitoring, 
and community education.
 In the distribution of AL through the child and 
family wellness (CFW) health providers, SHF adheres 
to the stipulated government recommendations 
(Figure 1). 
Figure 1
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NOTE: The testing is mostly recommended for 
children above five years and adults, for children 
under five years, testing is not a prerequisite for 
treatment but desirable where RDTs are available 
especially in low malaria endemic areas (2).
 This recommendation recognises the need to 
prevent or delay potential drug resistance that may 
arise, prevent drug abuse or misuse and also ensure 
adherence to the prescriptions. In line with the MOH 
requirements, a monitoring and evaluation system 
is in place to ensure that the guidelines are adhered 
to (2). 
 AL is administered as a six dose regimen.  The 
health provider explains the dosing schedule, and 
ensures the patient takes the first treatment dose at 
the clinic. The patients are counselled on malaria 
prevention, the need to return for review and to 
report any adverse reactions.
 The grassroots private sector has a key role 
in the delivery of lifesaving medicines and other 
interventions, but engaging them requires innovative 
approaches and careful assessment.  
 Sustainable Healthcare Foundation (SHF) has 
for the past seven years pioneered the application 
of an effective business format franchise model to 
distribute essential drugs and basic healthcare in 
rural Kenya. 
 Currently our reach is 65 outlets and we hope to 
reach 225 outlets in the next five years. The nurse-run 
clinics provide essential medicines and basic health 
care to approximately 400,000 people annually (3). 
Malaria is the commonest cause of illness, followed by 
upper respiratory tract infections (URTI), diarrhoea, 
intestinal worms and skin conditions. Malaria 
prevalence among patients who seek treatment at 
the clinics is estimated at 40% (1, 3).
 In the past twelve months SHF has been piloting 
a project to provide access to first line antimalarial 
medicines using ACTs in nine nurse-run CFW clinics 
with support from Exxon Mobil Foundation. This 
pilot project operates using four defined protocols 
namely, patient service, data collection, training and 
community education.
The role of medicine retailer programmes in the Kenyan 
National Malaria Strategy: In recent years, Kenya 
has experienced a number of initiatives aimed at 
improving service delivery of anti-malarial medicines 
using different approaches (4,5). The rationale for 
these initiatives is based on widespread recognition 
of the important role that private medicine retailers 
play in providing first line treatment for a variety of 
medical conditions in Kenya, including childhood 
fevers (6,7). The 2001 Kenya National Malaria 
Strategy recommends such programmes as a means 
of improving early access to effective antimalarial 
treatment for children with fever (8). 
 Between 2002 and 2005, the Division of Malaria 
Control (DoMC) in the Ministry of Health (MOH) 
supported 30 districts to obtain funding through the 
Global Fund for AIDS, TB and malaria (GFATM) to 
implement drug retailer programmes. A temporary 
working group in the DoMC developed guidelines 
for the implementation of medicine retailer 
programmes at district level in 2002 (9). On the basis 
of these guidelines, a research team from the Kenya 
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Medical Research Institute (KEMRI)-Wellcome Trust 
Programme has been working in collaboration with 
the DoMC and District Health Management Teams 
(DHMT) in three districts (Busia, Kwale and Makueni) 
to provide initial support for implementation and to 
evaluate medicine retailer programmes implemented 
between 2002 and 2005 (10). 
 In 2004, the DoMC recommended a new 
antimalarial drug policy to the Government of 
Kenya. The change concerned first line antimalarials 
(AM) for non-severe malaria, comprising a shift 
from the failing sulphadoxine pyrimethamine (SP) 
antimalarials to artemesinin based combination 
therapy (ACT). Initially this was to be implemented in 
the formal sector (government clinics and hospitals), 
followed by the formal private sector (private clinics 
and hospitals) and lastly in the informal retail sector 
(general sales) if experience and research supported 
this last phase and indicated appropriate mechanisms. 
In view of the failure rates seen for SP drugs in many 
parts of Kenya, the DoMC identified amodiaquine 
(AQ) antimalarials as the most appropriate over-the-
counter (OTC) preparations for first line treatment of 
malaria in the interim period. The retailer programme 
evaluations were therefore based on indicators related 
to AQ sales and use (10). 
MATERIALS AND METHODS
The pilot project has four main components. (i) 
Training of nurses running the rural clinics on drug 
dispensing according to the new malaria treatment 
guidelines, malaria diagnosis using rapid diagnostic 
test and record keeping.  (ii) Community education 
on care seeking for malaria, compliance to treatment 
and malaria prevention. (iii) A patient service 
component which involves history taking, basic 
physical examination, performing malaria diagnosis, 
dispensing of the new antimalarial artemether 
lumefantrine (AL) to malaria positive patients. 
 Patients who do not have malaria are examined 
to establish other causes of fever and are either treated 
by the nurses or referred to nearby health facilities 
with more qualified personnel as well as laboratory 
facilities. Patients are followed up to monitor recovery 
and for adverse drug reactions. (iv) Monitoring through 
routine record keeping and community surveys.  
Patient protocols
(i) The patient is greeted, welcomed and led to 
the consultation room. 
(ii) Personal details are taken.
(iii) Vital observations are taken: blood pressure, 
pulse, temperature, respiratory rate and 
weight 
(iv) Weight is important as it gives guidance on drug 
dosing. In the case of malaria, it will determine 
the dose category of AL to be used (doses are 
grouped into weight bands of 5-14 kg, 15-24 
kg, 25-34 kg and 35+ kg). 
(v) Medical history is taken, noting the presenting 
complaint, history of the present complaint, past 
medical history, family and social history. 
(vi) A physical examination is carried out with the 
patient on the couch.
(vii) The clinician then makes diagnosis or tentative 
diagnosis using the history and physical 
examination findings and informs the patient of 
the same and the need for confirmatory tests. 
(viii) In case of a tentative diagnosis of malaria, a rapid 
diagnostic test (RDT) is carried out and the result 
read after 15 minutes. If the test indicates one 
has malaria, AL is issued and patient advised 
on the dose, duration and frequency of taking 
the drug. The first dose is observed at the clinic, 
with demonstrations for the patient on how to 
take the drug and in the case of a child, how to 
crush and mix with clean water.  Paracetamol 
for pain and fever is also issued.
(ix) If a patient is too sick to be handled in the outlet, 
basic history and observations are taken and 
some first aid offered. A referral form is then 
filled and relatives directed where to take the 
patient.
(x) All patients are advised on a review date which 
is indicated on a TCA (To Come Again) card as 
well as report on any adverse drug reactions 
(ADR) (Pharmacovigilance).
(xi) Patients with ADR associated with AL 
are managed as per the manufacturer ’s 
recommendations.   
(xii) Patients with severe malaria are managed as per 
the recommendations in the malaria treatment 
guidelines.
Data collection protocols:  Figure 2 outlines the tools 
developed to collect data for monitoring project 
activities which are reported monthly from each 
outlet:
 Figure 2
Tools developed to collect data for monitoring project 
activities
• Daily patient register (DPR).
• AL requisition form as per weight categories.
• AL stock card as per weight categories.
• AL consumption form as per weight 
categories.
• RDT stock cards.
• RDT requisition forms.
• RDT consumption forms. 
• Malaria specific morbidity form separated to    
< 5 and > 5 age categories.
• Pharmacovigilance on adverse drug reactions 
(ADRs) form.
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Training protocols: A team consisting of SHF’s malaria 
project coordinator, health services manager, training 
and communication manager and health services 
officers have been trained as ToTs by Ministry of 
Health on the new MOH training guidelines for 
diagnosis and treatment of malaria.  This team 
conducts a three day residential training for nurses 
from the outlets. The training covers the following 
topics:
(i) New treatment guidelines.
(ii) Malaria diagnosis.
(iii) Theory and practicals on carrying out the rapid 
diagnostic tests.
(iv) Theory on malaria microscopy.
(v) Dispensing of AL/Pharmacovigilance.
(vi) Health education.
(vii) Record keeping.
Then, a one-day residential continuing education 
session is conducted after three months of 
implementation. The session includes, but is not 
limited to, the following topics:
(i) Project progress update.
(ii) Experience sharing.
(iii) Areas of the project that need emphasis.
(iv) Challenges and how to overcome them.
Community education protocols: In rolling out 
community education, SHF has developed scripts 
and information, education and communication 
(IEC) materials with messages and information on 
malaria treatment, prevention and control. SHF 
identifies comedian/theatre groups within the 
outlets that have experience in developing malaria 
messages into songs, drama and poems.  These groups 
are used to perform once every quarter at public 
meetings (Chief’s barazas) to educate the community 
in their vernacular about malaria. The theme of the 
community education is “Stop malaria…Save life… 
use AL. Follow dosage regimen of AL to completion for 
effective cure of malaria.”
During these public meetings or Chief’s Barazas the 
following is carried out:
(i) Talks on malaria/AL.
(ii) Skits on malaria/Al.
(iii) Songs on malaria/Al.
(iv) Poems on malaria/AL.
(v) Posters, leaflets and fliers on AL are 
distributed.
(vi) Caps and t-shirts with AL messages are 
distributed.
(vii) Messages--“Komesha Malaria… 0koa Maisha, 
Tumia AL” (Stop malaria…Save Life…Use AL).
(viii) Distribution of IEC materials in the form of 
calendars, fliers, brochures, leaflets and posters, 
t-shirts and caps.
 Other channels for community education that 
SHF requires every franchisee to use include, but are 
not limited to, the following:
(i) Outreaches/home visits.
(ii) One on one.
(iii) Schools.
(iv) Mosques/Churches.
(v) Organised community group meetings.
RESULTS 
Parasitological baseline survey: In order to determine 
the malaria prevalence at the project sites, a 
parasitological survey was carried out at 17 different 
CFW clinics in 17 market centres in three districts 
of SHF’s central region. The central region serves 
Kirinyaga, Embu and Mbeere districts of Kenya. A 
community mobilisation exercise for children under 
five was conducted with assistance from MoH staff 
and the Provincial administration.
 Blood samples were then taken from 2744 children 
aged 6-59 months and examined for malaria by experts 
from the Division of Vector Borne Diseases (DVBD) 
in Mwea. As an incentive, every child got a free ITN, 
while those who were sick got free treatment. 
 The survey was carried out in the months of 
October and November 2006, which represents a low 
malaria transmission season. Project sites that had at 
least one positive blood slide for malaria parasites 
were selected. A positive malaria slide detected in 
a site was indicative of malaria presence as well as 
active malaria transmission.
Findings of the parasitological survey: The survey 
confirmed active malaria transmission in, Kevote, 
Ugweri, Gatunduri, Nthagaiya and Ena markets in 
Embu district, of which all were selected as pilot sites. 
Ugweri market had the highest blood positivity rate 
among children aged 6-59 months. 
Selection of project sites: Project sites were selected 
based on: past malaria morbidity, malaria disease 
burden (after a parasitological survey to determine 
malaria prevalence), capacity of the franchisee 
to assimilate new products, and current business 
performance of the clinics. Ten outlets were selected 
which include five from Embu, three from Kirinyaga 
and two from Mbeere districts. AL was obtained from 
Kenya Medical Supplies Agency (KEMSA) through 
Division of Malaria Control (DoMC) on a quarterly 
basis and availed to the user free of cost while Rapid 
Diagnostic Tests (RDTs) were purchased through 
SHF procurement systems. RDTs were charged to 
the clients at a subsidised fee of Ksh 20. 
 In order to improve the tracking system, and 
as required by MoH because AL is a prescription-
only drug, the project hired two pharmaceutical 
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technologists to strengthen capacity of dispensing AL, 
monitor and manage AL as well as pharmacovigillance 
for adverse drug reaction (ADR). 
Community education: In rolling out community 
education, several channels were used including 
public meetings (Chief’s barazas), outreach/home 
visits, cultural theatre groups, schools and mosques/
churches. The theme of the community education is 
“Stop Malaria…Save Life. Follow dosage regimen of AL 
to completion for effective cure of malaria”. 
Table 1
Selected project sites
Name of CFW Clinic Locality/market District Franchisee
Tumaini Clinic* Ugweri Embu Mary Njue
By Grace Clinic* Gatunduri Embu Mary Njeru
Tender loving Care* Kevote Embu Tasiana Mateo
Msamaria Mwema* Nthagaiya Embu Reuben (Mercy)
Njiwa  Clinic* Ena Embu Jeane Kathangai
Njuka Clinic* Kiorugari Kirinyaga Daniel Kamanga
Huruma Clinic* Kiritiri Mbeere Rosemary M. Njagi
Arahuka Shop Kiandegwa Kirinyaga Isabella Maina
St. Judy Shop Gatwiri Kirinyaga Catherine Mutava
Karaba Shop Karaba Mbeere Jane Kiswili
* CFW clinics in the first phase of the study
Table 2
Distribution and supply of AL and RDTs to project sites, December 2006- November 2007
CFW clinics in the first phase of the study
Name of  Locality/ RDT   Quantities of AL issued               Total  
CFW Clinic market issued 5-14 15-24 25-34 35+ AL (%)  
      
Tumaini Ugweri  1900 300 120 120 900 1440 31.05
By Grace  Gatunduri 150 60 60 30 60 210 4.53
T L C Kevote 600 180 120 30 150 480 10.35
Msamaria  Nthagaiya 350 60 30 60 180 330 7.12
Njiwa Ena 700 90 60 30 150 330 7.12
Njuka Kiorugari 1050 180 120 86 450 836 18.03
Huruma  Kiritiri 475 90 60 60 60 270 5.82
Arahuka  Kiandegwa  250 90 60 30 141 321 6.92
St. Judy  Gatwiri  325 120 60 30 210 420 9.06
    Total 5825 1170 690 476 2301 4637 100
 To strengthen community education and outreach 
activities, two nurses were hired. Community 
education was carried out at several public meetings 
(Chiefs’ barazas) within the project site.  
 A total of 3,248 people were reached with 
education at barazas through the nine outlets. On 
average, at least two community meetings were held 
at each of the nine outlets.
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Figure 3
Malaria RDT positivity rate December 2006 to November 2007
Figure 4
AL consumption among positive malaria cases by category
Tumaini and Njuka clinics demanded more RDTs 
and AL because they had more clients and were 
located in high malaria endemic areas. This shows 
the importance of having update attendance record 
to determine the supplies for a push system.
 Initial supplies were based on a push system to 
the project sites but subsequent supplies are being 
replenished based on a pull system (demand from 
the project sites).
 Preliminary findings from this project show that 
a total 5,584 suspected malaria cases were tested at the 
project sites between December 2006 and November 
2007.  Out of these, 2,195 (39.3 %) were RDT positive 
while 412 were blood slide (BS) referral positive and 
all were treated for malaria with AL. By introducing 
definitive diagnosis for malaria (using RDTs) in 
our setting, we estimate 53.4% cost savings on AL 
compared to presumptive diagnosis (clinical). 
Figure 3 shows progressively higher percentages 
of positive malaria cases. This could either be due 
to increase in cases or due to improved diagnosis 
following community outreach.
 Figure 4 shows the AL consumption trends based 
on the various patient weight  (kgs) categories. The 
highest consumption was by those weighing 35 kgs 
and above followed by the 5-14 kgs category. The 
lowest was the 25-34 kg category. Arahuka and St. 
Judy clinics started their activities in March 2007 as 
they were in the second phase
DISCUSSION 
Malaria prevalence among patients (both the <5’s 
and> 5‘s) who had fever or were suspected to have 
malaria was about 40%(2195 out of 5584). These 
are the patients who tested positive for malaria. All 
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malaria positive patients received the right dose of AL 
according to their body weight.  The most commonly 
used AL category was that of children and adults >35 
kilograms. This was followed by the 5-14 kg category 
comprising mainly of the under fives an age group 
that is highly susceptible to malaria. The lowest was 
the 25-34 kg category made up of adolescents. This 
implies that when ordering for AL, more quantities 
of the category of 35+ kg were required while the 
category of 25-34 kg required fewer quantities. In 
view of the above and formerly as shown in Table 
2, it is important to have accurate data to enable 
the project to place orders for the requisition and 
distribution of AL and RDTs to the clinics. Three 
thousand two hundred and fourty eight community 
members were reached with malaria information; 
however, community expectations took longer to 
change as patients demanded AL even when the 
malaria diagnosis was negative. Initially, this led to 
the dispensing of other antimalarials to patients with 
malaria like symptoms even with a negative test. This 
demand decreased with more community education 
on the importance of the tests. 
 Engaging the private sector proved to be feasible 
and appropriate in malaria treatment based on 
diagnosis instead of presumptive treatment based 
on fever, reducing the use of expensive antimalarials 
by more than 50%, implying better patient care and 
cost savings on malaria treatment. 
 Over the twelve months, only two cases of adverse 
drug reactions (ADR) were reported in Njuka and 
Tumaini clinics. In the former a child experienced oral 
thrush after three days of taking AL. This could not 
directly be related to AL, other concomitant infections 
or drugs might have been responsible.  The patient 
in Tumaini developed pruritus which is one of the 
side effects documented by the drug manufacturer. 
The patient who developed pruritus discontinued AL 
treatment on day two and was given amodiaquine for 
three days while the one who developed oral thrush 
was put on clotrimazole oral paint for five days and 
both responded well.
 The current project is scheduled to expand to 
all the CFW clinics starting from mid 2008-2010 and 
serving hundreds of thousands of malaria victims 
every year. We believe that full deployment of this 
programme throughout an expanded network of 
clinics will significantly magnify its impact and that 
it could become the most effective malaria project of 
its kind in Africa. 
 The nurse-run clinics provide essential medicines 
and basic health care to approximately 400,000 people 
annually. Malaria is the commonest cause of illness. 
Exxon Mobil has been a valued partner in these 
first steps toward a better model for the sustainable 
provision healthcare in the developing world.  We 
look forward to a continuing partnership with Exxon 
Mobil for a long time to come.  
In conclusion, a micro-franchising system is an 
effective and sustainable way of improving access 
to effective health care by populations living in 
underserved rural areas of Africa. With appropriate 
supportive training and supervision, the system can 
adapt to changes in treatment guidelines and to new 
regimens.
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